Edwards Lifesciences officer proposes $194K sale

The notice identifies the shares as acquired through an employee stock option exercise, with broker payment for a cashless exercise.

Available on EDGAR 11/10/2026 - 04:13 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:12 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Edwards Lifesciences Corp officer Daniel J. Lippis gave notice of a proposed sale of 1,857 common shares, with an aggregate market value of $193,592.00 and an approximate sale date of November 10, 2026. The remarks state that the options may be sold over various dates.

The shares are listed as acquired through an employee stock option exercise, with broker payment for a cashless exercise. The notice lists February 13, 2026 as the Rule 10b5-1 plan adoption or instruction date. During the preceding three months, Lippis reported sales of 619 shares on August 11, September 11, and October 8, 2026, for gross proceeds of $56,967.00, $54,169.00, and $53,017.00, respectively.

Key Figures

Proposed sale: 1,857 shares Aggregate market value: $193,592.00 Shares sold: 619 shares +5 more

8 metrics

Proposed sale 1,857 shares Common shares; approximate sale date November 10, 2026

Aggregate market value $193,592.00 Shares listed for sale

Shares sold 619 shares August 11, 2026

Gross proceeds $56,967.00 Sale on August 11, 2026

Shares sold 619 shares September 11, 2026

Gross proceeds $54,169.00 Sale on September 11, 2026

Shares sold 619 shares October 8, 2026

Gross proceeds $53,017.00 Sale on October 8, 2026

Key Terms

Employee Stock Option Exercise, Cashless Exercise, Rule 10b5-1

3 terms

Employee Stock Option Exercise financial

"Employee Stock Option Exercise - See Remarks"

Cashless Exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EW shares did Daniel J. Lippis propose to sell?

The notice lists 1,857 common shares for sale, with an aggregate market value of $193,592.00 and an approximate sale date of November 10, 2026; it says the options may be sold over various dates.

What were Daniel J. Lippis's recent EW share sales?

The notice lists sales of 619 shares on August 11, September 11, and October 8, 2026. The respective gross proceeds were $56,967.00, $54,169.00, and $53,017.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002004380
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Lippis Daniel J.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	1857	193592.00	575000000	11/10/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/10/2026	Employee Stock Option Exercise - See Remarks	EDWARDS LIFESCIENCES CORPORATION			1857	11/10/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	08/11/2026	619	56967.00
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	09/11/2026	619	54169.00
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	10/08/2026	619	53017.00

144: Remarks and Signature

Remarks	The options on this filing may be sold over various dates.
Date of Notice	11/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daniel J. Lippis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)